| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 4,568 | 3,006 | ||
| Accounts receivable | 100 | 525 | ||
| Prepaid expenses | 386 | 462 | ||
| Other current assets | 11 | 27 | ||
| Total current assets | 5,065 | 4,020 | ||
| Other investment | 5,350 | 5,350 | ||
| Total assets | 10,415 | 9,370 | ||
| Accounts payable | 480 | 462 | ||
| Accrued research and development costs | 46 | 72 | ||
| Accrued expenses and other current liabilities | 351 | 266 | ||
| Total current liabilities | 877 | 800 | ||
| Preferred stock, no par value, 100,000,000 shares authorized and 351,037 shares of series a convertible preferred stock issued and outstanding at september 30, 2025 and december 31, 2024 | 0 | 0 | ||
| Common stock, no par value, 400,000,000 shares authorized at september 30, 2025 and december 31, 2024 3,814,260 and 2,710,096 shares issued at september 30, 2025 and december 31, 2024, respectively 3,695,158 and 2,545,922 shares outstanding at september 30, 2025 and december 31,2024, respectively | 0 | 0 | ||
| Paid-in capital | 279,759 | 277,815 | ||
| Accumulated deficit | -270,221 | -269,245 | ||
| Total stockholders' equity | 9,538 | 8,570 | ||
| Total liabilities and stockholders' equity | 10,415 | 9,370 | ||
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)